Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 284

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 284
---
 to these circumstances, both companies decided it would be mutually beneficial to terminate the MultiplAI Share Purchase Agreement. On August 11, 2024, MultiplAI, the Company, and Parent entered into a binding term sheet for a reseller license agreement (the “Reseller License Agreement”), pursuant to which MultiplAI granted OmnigenicsAI an exclusive license to market certain products in Latin America through December 31, 2030. This license applies to MultiplAI’s proprietary blood -based, laboratory -developedtest for detecting markers associated with conditions like calcified atherosclerotic plaque, coronary artery disease (“CAD”), and steatotic liver disease (the “MultiplAI Products”). Concurrently with the Restructuring, Parent has agreed to contribute to OmnigenicsAI certain receivables owed by MultiplAI to Parent pursuant to certain loan agreements. This binding term sheet was entered into in the context of negotiations relating to the termination of the MultiplAI Share Purchase Agreement. See “ Certain Agreements Related to the Business Combination — Reseller License Agreement” and “ Unaudited Pro Forma Combined Financial Information — Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of June 30, 2024.” On August 27, 2024, Parent, MultiplAI and the MultiplAI Shareholders (with APx’s consent) terminated the MultiplAI Share Purchase Agreement. As a result of such termination, OmnigenicsAI will not acquire MultiplAI, their business will not be combined pursuant to the Business Combination Agreement, and all rights and obligations of MultiplAI under the Business Combination Agreement ceased and terminated, subject to certain exceptions. For more information on the decision to terminate the MultiplAI Share Purchase Agreement, see “ — Decision to Terminate the MultiplAI Share Purchase Agreement.” Except as set forth above, no other terms of the Business Combination have been modified, and OmnigenicsAI and APx intend to complete the combination of our businesses (without the acquisition of MultiplAI) as set forth in the Business Combination Agreement. APx Board of Directors’ Reasons for the Approval of the Business Combination As described above, the APx Board, in evaluating the Business Combination, consulted with APx’s management and advisors. In reaching its unanimous decision to approve the Business Combination Agreement and the transactions contemplated by the Business Combination Agreement, the APx Board considered a range of factors, including, but not limited to, the factors discussed below. In light